Patents by Inventor Stephan Urban
Stephan Urban has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11973313Abstract: A diode laser arrangement includes at least one emitter, first and second cooling devices and a first connecting layer. The emitter is configured to emit a laser beam and is disposed between the first and second cooling devices. The first and second cooling devices are each configured for cooling the emitter. The emitter is connected to the first cooling device by the first connecting layer, and the first connecting layer has a connecting material or is composed of a connecting material selected from a group including gold, a gold alloy, silver, a silver alloy, a silver sintered material, copper, a copper alloy, nickel, a nickel alloy, palladium, a palladium alloy, platinum, a platinum alloy, rhodium, a rhodium alloy, iridium, an iridium alloy, germanium, a germanium alloy, tin, a tin alloy, aluminum, an aluminum alloy, indium, an indium alloy, lead and a lead alloy.Type: GrantFiled: June 18, 2019Date of Patent: April 30, 2024Assignee: TRUMPF Photonics, Inc.Inventors: Stephan Strohmaier, Arne-Heike Meissner-Schenk, Gerald Urban, Gerd Hansen, Christian Carstens
-
Publication number: 20240123025Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: ApplicationFiled: June 6, 2023Publication date: April 18, 2024Inventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
-
Patent number: 11841368Abstract: The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D virus (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.Type: GrantFiled: May 16, 2019Date of Patent: December 12, 2023Assignee: UNIVERSITÄT HEIDELBERGInventors: Florian Lempp, Stephan Urban
-
Publication number: 20230211003Abstract: The present invention relates to conjugate compounds which comprise a peptide moiety (a) which is preferably a hydrophobic modified preS-derived peptide of hepatitis B virus or a respective cyclic peptide, and a NTCP substrate moiety (b), which is preferably a bile acid. The present invention further relates to pharmaceutical compositions comprising at least one conjugate compound. The present invention further relates to medical uses of said conjugate compounds and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a said diseases and/or infections.Type: ApplicationFiled: October 9, 2020Publication date: July 6, 2023Inventors: STEPHAN URBAN, WALTER MIER
-
Patent number: 11401304Abstract: The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.Type: GrantFiled: December 15, 2016Date of Patent: August 2, 2022Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Stephan Urban, Yi Ni, Walter Mier
-
Publication number: 20210239701Abstract: The present invention relates to a polypeptide and a nucleic acid encoding the polypeptide for use in a method of detecting the presence of hepatitis D vims (HDV) and/or of diagnosing an HDV infection and/or of monitoring the treatment of an HDV infection. The present invention further relates to an in vitro method, an immunographic test device as well as a kit. In particular, the present invention relates to a point of care diagnostic for HDV infections.Type: ApplicationFiled: May 16, 2019Publication date: August 5, 2021Inventors: FLORIAN LEMPP, STEPHAN URBAN
-
Patent number: 10967044Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: GrantFiled: February 7, 2019Date of Patent: April 6, 2021Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
-
Publication number: 20200384070Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: ApplicationFiled: May 28, 2020Publication date: December 10, 2020Inventors: Volker CLEEVES, Stephan URBAN, Ralf KUBITZ
-
Patent number: 10716757Abstract: The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.Type: GrantFiled: October 11, 2016Date of Patent: July 21, 2020Assignee: Universität HeidelbergInventors: Gert Fricker, Walter Mier, Frieder Helm, Philipp Uhl, Stephan Urban
-
Patent number: 10618947Abstract: The present invention relates to a novel Hepatitis B virus (HBV) and/or Hepatitis D virus (HDV) receptor and its use for the development of cells, cell lines and non-human animals that are susceptible to HBV and/or HDV infection and can be used for immunological studies and/or for the screening of drugs, post-entry restriction factors and host dependency factors. It further relates to the use of the receptor for the identification of compounds useful in the treatment of HBV and/or HDV infection.Type: GrantFiled: November 12, 2013Date of Patent: April 14, 2020Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Stephan Urban, Yi Ni
-
Patent number: 10513539Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the compound(s) to be specifically delivered to the liver. The present invention furthermore relates to the use of the inventive hydrophobic modified peptides as well as to a method for the prevention and/or treatment of liver diseases or disorders.Type: GrantFiled: February 10, 2012Date of Patent: December 24, 2019Assignee: Ruprecht-Karls-Universitat HeidelbergInventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn
-
Patent number: 10413585Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: GrantFiled: November 12, 2013Date of Patent: September 17, 2019Assignee: RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERGInventors: Volker Cleeves, Stephan Urban, Ralf Kubitz
-
Patent number: 10363323Abstract: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The present invention furthermore relates to the diagnostic use of the inventive hydrophobic modified peptides as well as to a method for the diagnosis of liver diseases or disorders.Type: GrantFiled: February 10, 2012Date of Patent: July 30, 2019Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Walter Mier, Stephan Urban, Stefan Mehrle, Uwe Haberkorn, Thomas Müller, Vasileios Askoxylakis
-
Patent number: 10323068Abstract: The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies.Type: GrantFiled: November 18, 2015Date of Patent: June 18, 2019Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Philippe Gripon, Stephan Urban
-
Publication number: 20190151406Abstract: The present invention relates to lipopeptide-based compounds for use in the diagnosis, prevention and/or treatment of a liver disease or condition, preferably liver involved metabolic diseases, as well as in the control or modification of the cholesterol level or cholesterol uptake and, thus, diagnosis, prevention and/or treatment of a cardiovascular disease. The present invention furthermore relates to an in vitro or in vivo assay or method for testing or measuring the NTCP-mediated transport of test compound(s). The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a liver disease or condition, comprising administering a therapeutically effective amount of a lipopeptide-based compound to a patient. The present invention furthermore relates to a method for the diagnosis, prevention and/or treatment of a cardiovascular disease.Type: ApplicationFiled: February 7, 2019Publication date: May 23, 2019Inventors: Volker CLEEVES, Stephan URBAN, Ralf KUBITZ
-
Publication number: 20180354993Abstract: The present invention relates to cyclic NTCP targeting peptides which are preS-derived peptides of hepatitis B virus (HBV). The present invention further relates to pharmaceutical compositions comprising at least one cyclic peptide. The present invention further relates to medical uses of said cyclic peptides and the pharmaceutical compositions, such as in the diagnosis, prevention and/or treatment of a liver disease or condition, and/or in the inhibition of HBV and/or HDV infection. The present invention further relates to methods of diagnosis, prevention and/or treatment of a liver disease or condition and/or the inhibition of HBV and/or HDV infection.Type: ApplicationFiled: December 15, 2016Publication date: December 13, 2018Inventors: Stephan URBAN, Yi NI, Walter MIER
-
Publication number: 20180303755Abstract: The present invention relates to liposomal compositions, comprising liposomes containing tetraether lipids (TELs), and further comprising the lipopeptide Myr-HBVpreS/2-48 (Myrcludex B) as part of said liposomes, as well as uses thereof for the prevention or treatment of hepatic disorders or diseases, and/or for the oral hepatic delivery of therapeutic and/or diagnostic agents.Type: ApplicationFiled: October 11, 2016Publication date: October 25, 2018Applicant: Universität HeidelbergInventors: Gert Fricker, Walter Mier, Frieder Helm, Philipp Uhl, Stephan Urban
-
Patent number: 9868768Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are versatile vehicles for the specific delivery of compounds to the liver, preferably to hepatocytes, in vitro as well as in vivo. Any kind of compound, but in particular drugs, such as interferons, viral reverse transcriptase inhibitors or core assembly inhibitors, and/or labels can be specifically targeted to the liver and so be enriched in the liver. This liver targeting can further be used for the targeted diagnosis, prevention and/or treatment of liver diseases or disorders, such as hepatitis, malaria, hepatocellular carcinoma (HCC), as well as for the prevention of HAV, HBV, HCV and/or HDV infection. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified preS-derived peptide(s) and the compound(s) to be specifically delivered to the liver.Type: GrantFiled: January 26, 2009Date of Patent: January 16, 2018Assignee: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERGInventors: Walter Mier, Uwe Haberkorn, Stephan Urban
-
Patent number: 9641053Abstract: A connecting element between a motor and a control unit includes a flat base plate having contact elements and an, in particular centered, opening. The base plate further includes a shaft around the opening. A first seal is provided at the edge of the base plate and a second seal is provided at the upper edge of the shaft.Type: GrantFiled: March 1, 2012Date of Patent: May 2, 2017Assignee: Robert Bosch GmbHInventors: Thomas Hennecke, Andre Skuppin, Stephan Urban
-
Patent number: 9562076Abstract: The present invention relates to hydrophobic modified preS-derived peptides of hepatitis B virus (HBV) which are derived from a HBV preS consensus sequence and are N-terminal preferably acylated and optional C-terminal modified. These hydrophobic modified preS-derived peptides of HBV are very effective HBV entry inhibitors as well as HDV entry inhibitors and are, thus, suitable for the inhibition of HBV and/or HDV infection, prevention of primary HBV and/or HDV infection as well as treatment of (chronic) hepatitis B and/or D. The present invention further relates to pharmaceutical and vaccine compositions comprising these hydrophobic modified preS-derived peptides of HBV.Type: GrantFiled: January 26, 2009Date of Patent: February 7, 2017Assignee: RUPRECHT-KARLS-UNIVERSITÄT-HEIDELBERG (Rektorat)Inventors: Walter Mier, Stephan Urban